Effects of a lyophilized aqueous extract of Feretia apodanthera Del. (Rubiaceae) on...

**Article** in *Epilepsy & Behavior* · February 2015

DOI: 10.1016/j.yebeh.2014.11.022

**CITATIONS**
7

**READS**
193

**12 authors**, including:

- **Germain Sotoing Taiwe**
  University of Buea
  50 PUBLICATIONS 318 CITATIONS
  SEE PROFILE

- **Gwladys Temkou Ngoupaye**
  University of Dschang, Dschang, Cameroon
  18 PUBLICATIONS 148 CITATIONS
  SEE PROFILE

- **Kouemou Nadege emegam**
  University of Buea
  5 PUBLICATIONS 17 CITATIONS
  SEE PROFILE

- **Elisabeth Ngo Bum**
  University of Maroua
  58 PUBLICATIONS 626 CITATIONS
  SEE PROFILE

**Some of the authors of this publication are also working on these related projects:**

- Medicinal Spices and Vegetables from Africa [View project]

  It is my Ph. D Project. the proposal of my Ph.D work is intitulate " Anticonvulsivant and antiepileptogenic properties of decoction of the leaves of Momordica cissoides L.¶ (Cucurbitaceae) ¶ and development test of one phyto-drug . [View project]
Effects of a lyophilized aqueous extract of *Feretia apodanthera* Del. (Rubiaceae) on pentylenetetrazole-induced kindling, oxidative stress, and cognitive impairment in mice


a Department of Zoology and Animal Physiology, Faculty of Sciences, University of Buea, P.O. Box 63, Buea, Cameroon
b Department of Biological Sciences, Higher Teachers’ Training College, University of Yaoundé 1, P.O. Box 47, Yaoundé, Cameroon
c Department of Animal Biology and Physiology, Faculty of Science, University of Yaoundé I, P.O. Box 812, Yaoundé, Cameroon
d Department of Biological Sciences, Faculty of Science, University of Ngaoundéré, P.O. Box 454, Ngaoundéré, Cameroon

⁎ Corresponding author.
E-mail address: eli_bum@yahoo.fr (E. Ngo Bum).

Abstract

*Feretia apodanthera* Del. (Rubiaceae) is extensively used in ethnomedicine in Cameroon and Nigeria for epilepsy, febrile convulsions, and rheumatic pains and for enhancing cognitive performance. The aim of the present study was to examine the effects of a lyophilized aqueous extract of *F. apodanthera* on the course of kindling development, kindling-induced learning deficit, oxidative stress markers, and cholinesterase activity in pentylenetetrazole (PTZ)-kindled mice. Pentylenetetrazole, 30 mg/kg, induced kindling in mice after 30.00 ± 1.67 days. The aqueous extract of *F. apodanthera* showed dose-dependent antiseizure effects. *Feretia apodanthera* (150–200 mg/kg) significantly increased the latency to myoclonic jerks, clonic seizures, and generalized tonic–clonic seizures. The extract also improved the seizure score and decreased the number of myoclonic jerks. Pentylenetetrazole kindling induced significant oxidative stress and cognitive impairment which were reversed by pretreatment with *F. apodanthera* in a dose-dependent manner. The significant decrease in cholinesterase activity observed in the PTZ-kindled mice was reversed by pretreatment with the *F. apodanthera* extract. The results indicated that pretreatment with the aqueous extract of *F. apodanthera* antagonizes seizures, oxidative stress, and cognitive impairment in PTZ-kindled mice. The aqueous extract of *F. apodanthera* also showed anxiolytic activities, but the inhibition of memory impairment was not attributed to the anxiolytic activities of the plant. These results thus suggest the potential of *F. apodanthera* as an adjuvant in epilepsy both to prevent seizures as well as to protect against seizure-induced oxidative stress and memory impairment.

© 2014 Elsevier Inc. All rights reserved.

1. Introduction

Epilepsy is the second most common neurological disorder after stroke, affecting at least 50 million persons worldwide [1]. It shows a prevalence rate of 1–2% of the world population [2]. Various anticonvulsant agents are available to grapple with this neurological disorder. Dose-related neurotoxicity, cognitive impairment, and a range of systemic side effects are the major problems caused by antiepileptic drugs [3]. Despite treatment with available antiepileptic drugs, epilepsy remains refractory in one-third of patients. Further, adverse effects associated with antiepileptic drugs and recurrent seizures limit their use. Increasing data from experimental and clinical reports suggest the involvement of oxidative stress in the pathophysiology of epilepsy [4]. Ongoing research on certain plant products has paved the way towards the development of a newer category of antiepileptic drug therapies [5,6]. The stem bark of *Feretia apodanthera* Del. (Rubiaceae) is being used empirically in traditional medicine in Cameroon to treat epilepsy and diseases related to the brain like agitation, anxiety, infantile convulsions, headaches, insomnia, pains, and schizophrenia according to our traditional healers and the literature [7–10]. In Senegal, the leaves of *F. apodanthera* are used to treat different urinary and renal infections. The plant is also used to treat stomach aches, nausea, and syphilis, as a calming agent for agitated mental conditions, and for enhancing cognitive performance [11]. The aim of this study was to evaluate the effects of a lyophilized aqueous extract of *F. apodanthera* on the course of kindling development, kindling-induced learning deficit, and oxidative stress in PTZ-kindled mice. Its effect on brain cholinesterase activity was also evaluated. Part of the results was published in abstract form [12].
2. Materials and methods

2.1. Plant material

The stem bark of *F. apodanthera* was collected from the North Region of Cameroon in April 2009. The botanical identification of the plant was done by the National Herbarium of Cameroon where the voucher specimen was conserved under the reference number 31225/HNC.

2.2. Preparation of the aqueous extract

The stem bark was separated, cleaned, sun-dried, and pulverized using a mechanical grinder. The powdered material was extracted with distilled water (50 g powder per 375 mL water) by cold maceration for 24 h, filtered through Whatman no. 1 filter paper, and freeze-dried (FreeZone® Dry 4.5, USA). This gave a yield of 8.62% (w/w). The freeze-dried extract was then subsequently reconstituted in distilled water at appropriate concentrations for the various experiments and administered orally in a volume of 10 mL/kg of body weight.

2.3. Preliminary qualitative phytochemical analysis

Preliminary phytochemical analysis of the aqueous extract of *F. apodanthera* was done using the following chemicals and reagents: flavonoids (NaCl and HCl), alkaloids (with Mayer’s and Dragendorff’s reagents), saponins (foaming test), tannins (FeCl₃), glycosides (NaCl and Fehling’s solutions A and B), cardiac glycosides (Salkowski test), anthraquinones (Bornträger’s reaction), phenols (FeCl₃ and K₃Fe(CN)₆), and lipids (filter paper) [13].

2.4. Drugs and chemicals

Diazepam (DZP), pentylenetetrazole (PTZ), sodium valproate (SVA), reduced glutathione, thiobarbituric acid, n-butanol, pyridine, sodium dodecyl sulfate, 5′,5′-dithiobis (2-nitrobenzoic acid) (DTNB), trichloroacetic acid, acetylthiocholine iodide, butyrylthiocholine iodide, and all other chemicals and reagents used in biochemical and preliminary phytochemical estimations were obtained from Sigma Chemical, USA.

2.5. Animal

The experiments were conducted using male Swiss mice (26–30 g). All animals were housed in a controlled environment, with free access to food and water, and were maintained on a 12 h light–dark cycle. All experiments were performed according to the Cameroon National Ethical Committee (ref. no FW-IRB00001954) for animal handling and experimental procedure. Twelve hours before behavioral testing, the mice were deprived of food to enhance their motivation to perform the test [14]. All behavioral tests were performed between 8:00 a.m. and 6:00 p.m.

2.6. Experimental design

Animals were randomly divided into eight groups of six animals each. The first group received saline intraperitoneally while the second to seventh groups were administered PTZ (30 mg/kg; i.p.) dissolved in saline on every second day (48 ± 2 h). One hour before administration of PTZ, the first and second groups received distilled water and the third to sixth groups were administered aqueous extract of *F. apodanthera* (50, 100, 150, and 200 mg/kg, respectively) orally through an intragastric feeding tube. Group seven animals were administered sodium valproate (300 mg/kg) intraperitoneally. Pentylenetetrazole was administered up to day 43 or until stage 5 seizures on two consecutive trials were achieved. In group eight, aqueous extract of *F. apodanthera* (200 mg/kg) was administered alone to study its per se effect, if any, on cognitive functions and biochemical parameters. Elevated plus-maze and M-maze tests were performed 24 and 48 h after the last administration of PTZ. Animal behaviors were manually recorded by two blinded experimenters holding stopwatches. Following the behavioral test, the animals were sacrificed and the whole brain was dissected for the estimation of markers of oxidative stress and brain cholinergic status. In addition, elevated plus-maze and open-field tests were done in naïve mice.

2.7. Kindling induction

For PTZ kindling, a subconvulsant dose of PTZ (30 mg/kg in a volume of 10 mL/kg of body weight) was injected intraperitoneally on every second day (i.e., day 1, day 3, day 5, ...). Pentylenetetrazole was administered up to day 43 (22nd injection) or until stage 5 seizures on two consecutive trials were achieved. Seizure activity was evaluated using the following scale [15]: stage 0: no response; stage 1: hyperactivity and vibrissal twitching; stage 2: head nodding, head clonus, and myoclonic jerk; stage 3: unilateral forelimb clonus; stage 4: rearing with bilateral forelimb clonus; and stage 5: generalized tonic–clonic seizures with loss of righting reflex. The number of myoclonic jerks and the latencies to myoclonic jerks and generalized tonic–clonic seizures were recorded. The latencies were transformed into seizure scores [16] which were calculated using the following formula: \( S = 1 - \left( \frac{\text{control latency}}{\text{drug seizure latency}} \right) \). Animals were considered kindled if they exhibited stage 5 seizures on two consecutive trials. The score was zero for animals which developed seizures and one for animals that did not develop seizures. Animals were also observed for 24-h mortality.

2.8. Behavioral tests

2.8.1. Elevated plus-maze test with PTZ-kindled mice

Cognitive impairment in mice was assessed using an elevated plus maze. The apparatus was made up of two open arms (16 cm × 5 cm) and two closed arms (16 cm × 5 cm × 10 cm) that extended from a common central platform (5 cm × 5 cm). The entire maze was elevated to a height of 50 cm above the floor level [17]. In the first trial, the time that the animal took to enter a closed arm with all four limbs when placed at the end of one open arm facing away from the central platform was recorded as the initial transfer latency. A 60-s cutoff was set. The mouse was then allowed to move freely in the maze regardless of open and closed arms for another 10 s. Twenty-four hours later, a retention transfer latency test was performed in the same way as in the acquisition trial. The mice were again put into the elevated plus maze. If the mice did not enter the enclosed arm within 60 s on the second trial, the transfer latency was assigned 60 s.

2.8.2. T-maze test with PTZ-kindled mice

The T-shaped maze was made of gray wood and consisted of a start arm and two choice arms. Each arm was 30 cm × 10 cm × 20 cm (length × width × height). A recessed black plastic cup (3 cm in diameter, 1 cm in depth) containing food was placed on the floor at the end of each choice arm. A day before the experiment, each animal was placed in the start position (at the end of the start arm) for a 10-min exploration phase with one arm of the maze open and then returned to their home cage. After a delay of 1 day, the animals were reintroduced to the T-maze for a 5-min testing period. During the retraining (the two choice arms were opened), animals were randomly placed in a start arm and the number of visits and the time spent in the two arms were assessed [18].

2.8.3. Elevated plus-maze test with naïve mice

The apparatus was the same as in Section 2.8.1. Mice were treated with distilled water for the negative control group, with diazepam (3 mg/kg) for the positive control group, and with different doses of the aqueous extract of *F. apodanthera* for the tested groups. One hour after treatment, mice were individually placed on the EPM center.
platform facing an open arm and observed for 5 min [19,20]. The number of entries by each animal into the open or closed arms and the time spent by each animal on either open or closed arms (conventional parameters) were recorded with stopwatches by two trained experimenters. The center platform time and some ethological parameters like rearing and head dipping were also recorded.

2.8.4. Open-field test with naïve mice

One hour after appropriate treatment administration, naïve mice were placed in the center of an open field. The open field used was a wooden square box: 40 cm × 40 cm × 45 cm, and the floor was divided into 16 smaller squares of equal dimensions (10 cm × 10 cm). Animals placed one by one in the center of the box could explore the box for 5 min. Mice were observed for 5 min in order to evaluate the effects of the plant both on the exploratory activity and on anxiety [19,21]. Hand-operated counters and stopwatches were used to score the number of crossings (number of square floor units entered), rearing (number of times that the animal stood on its hind legs), grooming, and defecation. The positive control group received diazepam at a dose of 0.3 mg/kg.

2.9. Biochemical tests

Following the behavioral testing with kindled mice, the mice were decapitated under ether anesthesia and the brains were quickly removed, cleaned with ice-cold saline, and stored at −80 °C.

2.9.1. Tissue preparation

The whole brain of each mouse was dissected out and divided into two cerebral hemispheres for biochemical estimations. From one half, 10% (w/v) homogenate was prepared with ice-cold 0.1 M phosphate buffer (pH 7.4), and the lipid peroxidation product and reduced glutathione were assessed. With the other half, 10% (w/v) homogenate was prepared with 0.1 M Tris–HCl buffer containing 1% Triton-X and was used to assess cholinesterase activity.

2.9.2. Brain lipid peroxidation

Malondialdehyde (MDA), a measure of lipid peroxidation, was measured as described by Jainkang et al. [22]. The reagents 1.5 mL acetic acid (20%), pH 3.5, 1.5 mL thiobarbituric acid (0.8%), and 0.2 mL sodium decyl sulfate (8.1%) were added to 0.1 mL of processed tissue samples and then heated at 100 °C for 60 min. The mixture was cooled with tap water and 5 mL of n-butanol/pyridine (15:1), and 1 mL of distilled water was added. The mixture was vortexed vigorously. After centrifugation at 4000 rpm for 10 min, the organic layer was separated and absorbance was measured at 532 nm using a spectrophotometer. The concentration of MDA is expressed as nmol/g tissue.

2.9.3. Reduced brain glutathione

Reduced brain glutathione (GSH) was measured according to the method of Ellman [23]. An equal quantity of homogenate was mixed with 10% trichloroacetic acid and centrifuged to separate the proteins. To 0.01 mL of this supernatant, 2 mL of phosphate buffer (pH 8.4), 0.5 mL of 5’5’-dithiobis (2-nitrobenzoic acid), and 0.4 mL of double-distilled water were added. The mixture was vortexed and the absorbance read at 412 nm within 15 min. The concentration of reduced glutathione was expressed as mg/g tissue.

2.9.4. Brain cholinergic status

The cholinergic markers acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) were estimated in the mouse brain according to the method of Ellman [24]. The assay is a spectrophotometric method that involves two linked reactions to produce a colored compound. Briefly, 10 mM DTNB in 0.1 M Tris–HCl buffer (pH 8.0), 100 µL of supernatant, and 30 mM butyrylthiocholine iodide as substrate were added for AChE estimation. For BChE estimation, 10 mM DTNB in 0.1 M Tris–HCl buffer (pH 8.0), 300 µL of supernatant, and 7.5 mM butyrylthiocholine iodide as substrate were added. Absorbance was measured at 412 nm for 3 min at 30-second intervals using a spectrophotometer. Acetylcholinesterase activity is expressed as µmol of acetylthiocholine iodide hydrolyzed/mg of protein/min, while BChE activity is expressed as µmol of butyrylthiocholine iodide hydrolyzed/mg of protein/min.

2.10. Statistical analysis

Data were expressed as mean ± standard error of the means (S.E.M.) per group. Statistical differences between control and treated groups were tested by two-way analysis of variance (ANOVA), followed by the Newman–Keuls post hoc test. The differences were considered significant at p < 0.05. The statistical package used for the analysis was GraphPad Prism 5.01 for Windows (GraphPad Prism Software, San Diego, CA, USA).

3. Results

3.1. Preliminary qualitative phytochemical analysis of the lyophilized aqueous extract of F. apodanthera

The aqueous extract of F. apodanthera contained flavonoids, alkaloids, saponins, tannins, glycosides, anthraquinones, and phenols but not cardiac glycosides and lipids.

3.2. Effects of F. apodanthera on the development of PTZ kindling

Repeated administration of a subconvulsant dose of PTZ (30 mg/kg) on alternate days resulted in increasing convulsive activity leading to generalized tonic–clonic seizures (stage 5) after 30.00 ± 1.67 days (16 injections) in negative control mice. One-way ANOVA showed a significant difference in the development of kindling among the treated groups [F(7, 32) = 51.46, p < 0.05]. The aqueous extract of F. apodanthera at doses of 50 and 100 mg/kg did not modify the course of the development of kindling induced by PTZ. However, the higher doses of the aqueous extract (150 and 200 mg/kg) inhibited the development of kindling (p < 0.05) since none of the animals could achieve stage 5 even after 43 days (22 injections of PTZ 30 mg/kg). The dose 300 mg/kg of sodium valproate also significantly (p < 0.05) delayed the course of the development of kindling induced by PTZ similarly to that in the F. apodanthera (150 and 200 mg/kg) groups (Fig. 1).

Fig. 1. Development of pentylenetetrazol-evoked kindling. Histograms represent the latency (in days) to reach generalized tonic–clonic seizures (stage 5). Results are expressed as mean ± S.E.M. for 6 animals. *p < 0.05 compared to the saline-treated PTZ group (two-way ANOVA followed by Newman–Keuls post hoc test); DW = distilled water, FA100 = lyophilized aqueous extract of Feretia apodanthera 100 mg/kg, Sal = saline, and SVA = sodium valproate.
3.3. Effects of F. apodanthera on seizures in PTZ-kindled mice

The aqueous extract of F. apodanthera and sodium valproate caused a dose-dependent increase in the latency to myoclonic jerks [F(7, 34) = 109.52, p < 0.001] as well as the latency to generalized tonic–clonic seizures [F(7, 26) = 97.13, p < 0.001] and a decrease in the number of myoclonic jerks [F(7, 42) = 116.24, p < 0.001] compared to the distilled water–treated PTZ mice.

The latency to myoclonic jerks increased from 45.17 ± 4.78 s in the distilled water–treated PTZ mice to 110.17 ± 5.22 s (p < 0.05) and 160.50 ± 5.17 s (p < 0.001) in the groups administered with F. apodanthera 150 and 200 mg/kg, respectively (Fig. 2).

The number of myoclonic jerks decreased from 55.33 ± 3.55 in the distilled water–treated PTZ mice to 110.17 ± 5.22 s (p < 0.05), 128.3 ± 3.17 (p < 0.001), and 7.00 ± 1.33 (p < 0.001) in the groups administered with F. apodanthera 100, 150, and 200 mg/kg, respectively (Fig. 3).

An increase in the onset of clonic seizures was observed [F(7, 41) = 135.74, p < 0.001]. Feretia apodanthera significantly increased the latency to clonic seizures from 61.83 ± 8.61 s in the distilled water–treated PTZ mice to 176.17 ± 7.55 s (p < 0.001), 273.50 ± 9.83 s (p < 0.01), and 365.33 ± 11.1 s (p < 0.001) in F. apodanthera 100-, 150-, and 200-mg/kg-treated groups, respectively (Fig. 2).

The aqueous extract of F. apodanthera also increased the latency to generalized tonic–clonic seizures from 175.83 ± 15.55 s in the distilled water–treated PTZ mice to 350.67 ± 26.11 s (p < 0.05), 399.33 ± 11.22 s (p < 0.01), and 496.50 ± 31.33 s (p < 0.01) in the groups administered with F. apodanthera 100, 150, and 200 mg/kg, respectively (Fig. 2).

There was a significant difference in the duration of generalized tonic–clonic seizures among the different groups [F(7, 42) = 109.71, p < 0.001]. The duration of generalized tonic–clonic seizures decreased from 183.3 ± 1.33 s in the distilled water–treated PTZ mice to 71.7 ± 0.55 s (p < 0.05), 450 ± 0.67 s (p < 0.01), and 333 ± 0.44 s (p < 0.001) in the groups administered with 100, 150, and 200 mg/kg of the aqueous extract, respectively (Fig. 3).

Seizure scores among the groups were also significantly different [F(7, 32) = 172.41, p < 0.001]. It increased from 0 in the distilled water–treated PTZ mice to 0.56 ± 0.04 (p < 0.05) and 0.64 ± 0.05 (p < 0.01) in the groups administered with F. apodanthera 150 and 200 mg/kg, respectively (Fig. 4).

3.4. Effects on cognitive impairment

3.4.1. Effects of F. apodanthera on the elevated plus-maze test in PTZ-kindled mice

There was no significant difference in initial transfer latency [F(7, 25) = 79.41, p > 0.064] from the open arm to the closed arm among the groups, whereas there was a significant difference in retention transfer latency [F(7, 35) = 114.62, p < 0.001]. Pentyleneetetrazole kindling caused a significant increase in the retention transfer latency from 9.67 ± 1.22 s in the distilled water + saline–treated group to 39.33 ± 1.89 s in the distilled water–treated PTZ mice (Fig. 5). The aqueous extract of F. apodanthera produced a dose–dependent reversal of the effect of PTZ–induced kindling on the retention transfer latency. Thus, the retention transfer latency decreased from 39.33 ± 1.89 s in the distilled water–treated PTZ mice to 19.33 ± 3.11 s (p < 0.01), 18.83 ± 3.22 s (p < 0.01), and 11.33 ± 1.67 s (p < 0.001) in groups administered with F. apodanthera 100, 150, and 200 mg/kg, respectively. Sodium valproate reduced the retention transfer latency to 8.83 ± 1.28 s. The
3.4.2. Effects of F. apodanthera on the T-maze test in PTZ-kindled mice

On the retrial, animals first entered the familiar arm that contained food and after they started exploring the novel arm. The time spent in the novel arm was significantly increased compared with the time spent in the start and other arms in the groups administered with the aqueous extract of F. apodanthera. The time spent in the novel arm was 134.67 ± 5.78 (p < 0.05) and 136.33 ± 7.33 (p < 0.05) in the groups administered with 150 and 200 mg/kg of F. apodanthera, respectively, that is about 2-fold of that in the distilled water-treated PTZ mice (59.50 ± 6.67). This time slightly increased in the groups administered with 50 mg/kg (100.33 ± 4.55; p < 0.05) and 100 mg/kg (112.00 ± 9.67; p < 0.05). The effect of the plant extract was similar to the effect of sodium valproate, a known anticonvulsant compound (Fig. 6A). Feretia apodanthera also increased the number of entries into the novel arm from 6.83 ± 2.11 in the distilled water-treated PTZ mice to 16.16 ± 0.83 (p < 0.01) and 18.00 ± 1.33 (p < 0.01) in the groups administered with 150 and 200 mg/kg of the aqueous extract, respectively (Fig. 6B).

3.5. Effects on anxiety and locomotion

3.5.1. Effects of F. apodanthera on the elevated plus-maze test in naïve mice

The aqueous extract of F. apodanthera increased the number of entries in the open arms (p < 0.001), the % of entries in the open arms (p < 0.001), and the % of time spent in the open arms (p < 0.001) from 0.17, 2.57%, and 0.17% in the control group to 1.33, 66.67%, and 66.89% in the group treated with the aqueous extract of F. apodanthera at the dose of 200 mg/kg, respectively. Diazepam (3 mg/kg, i.p.) also induced an increase in the % of entries and time spent in the open arms of the EPM (Table 1, Fig. 7A). Like diazepam, F. apodanthera induced a significant reduction in the number of closed arm entries (p < 0.001) and the % of closed arm time (p < 0.001) from 6.33 and 95.44% in the control group to 0.67 and 3.39% in the group treated with the F. apodanthera aqueous extract at the dose of 200 mg/kg, respectively (Fig. 7B). In addition, the ratio of open entries/total entries vs. closed entries/total entries strongly and significantly increased with the doses of F. apodanthera from 2.63 in the control group to 200.00 in the group treated with F. apodanthera at the dose of 200 mg/kg (p < 0.001). The number of rearings and that of head dipping were also reduced by both diazepam and F. apodanthera (Table 1).

3.5.2. Effects of F. apodanthera on the open-field test in naive mice

Like in the EPM test, the number of rearings was decreased (p < 0.001) by both F. apodanthera and diazepam. They also decreased (p < 0.001) the mass of fecal boli. Controversially, the aqueous extract of F. apodanthera increased crossing (p < 0.001), grooming (p < 0.001), and the time spent by mice in the center (p < 0.001) (Table 2).

3.6. Biochemical measurements

3.6.1. Effects of F. apodanthera on brain MDA levels in PTZ-kindled mice

Pentylenetetrazole kindling significantly increased (p < 0.001) the brain MDA level from 128.754 ± 16.193 nmol/g wet tissue in the distilled water + saline-treated mice to 427.493 ± 18.157 nmol/g wet tissue in the distilled water–treated PTZ mice. Feretia apodanthera antagonized the increased brain MDA levels due to PTZ kindling in a dose-dependent manner. The MDA levels significantly decreased from 427.493 ± 18.157 nmol/g wet tissue in the distilled water–treated PTZ mice to 178.374 ± 22.633 nmol/g wet tissue (p < 0.01), 137.518 ± 18.491 nmol/g wet tissue (p < 0.001), and 127.342 ± 21.352 nmol/g wet tissue (p < 0.001) in groups administered with F. apodanthera 100,
150, and 200 mg/kg, respectively. Feretia apodanthera per se (200 mg/kg) caused a decrease in oxidative stress \((p < 0.001)\), based on whole brain MDA levels, compared with the distilled water-treated PTZ mice (Table 3).

### 3.6.2. Effects of F. apodanthera on brain glutathione levels in PTZ-kindled mice

The brain GSH was significantly lower \((p < 0.001)\) in the group administered with distilled water + PTZ compared to the groups administered with distilled water + saline. Feretia apodanthera reversed the decreased brain GSH levels. At doses of 150 and 200 mg/kg, F. apodanthera significantly increased the levels of brain GSH to 173.147 ± 16.328 μg/g wet tissue \((p < 0.05)\) and 191.532 ± 12.492 μg/g wet tissue \((p < 0.05)\), respectively. Feretia apodanthera (200 mg/kg) alone also caused a significant increase \((198.713 ± 13.715 μg/g wet tissue; p < 0.05)\) in the brain GSH levels (Table 3).

### 3.6.3. Effects of F. apodanthera on cholinesterase activity

The activity of AChE and BChE significantly decreased in the distilled water-treated PTZ mice \((p < 0.01)\) compared with the distilled water + saline-treated group. A significant increase of AChE and BChE activity was observed in mice pretreated with F. apodanthera (100, 150, and 200 mg/kg) and sodium valproate. Feretia apodanthera (200 mg/kg) alone also significantly increased \((p < 0.01)\) AChE and BChE activity (Table 3).

### 4. Discussion

Kindled seizures are widely accepted as an animal model of temporal lobe epilepsy, wherein repeated subthreshold brain stimulation (electrical or chemical) leads to behavioral signs of tonic and clonic seizures [25]. In the present study, a subconvulsant dose of PTZ when given intraperitoneally on alternate days induced kindling in mice after 30 days. The groups which were administered with the aqueous extract of F. apodanthera showed dose-dependent protection against seizures. Feretia apodanthera increased the latencies to myoclonic jerks, clonic seizures, and generalized tonic–clonic seizures as well as the duration of generalized tonic–clonic seizures. Feretia apodanthera in a dose-dependent manner decreased the number of myoclonic jerks and the seizure score. The protection against PTZ-induced kindling in mice and seizures in kindled mice suggest that F. apodanthera may have anticonvulsant properties against partial epilepsy, especially temporal lobe epilepsy [26]. The seizure protection offered by F. apodanthera (200 mg/kg, p.o.) was comparable to the standard antiepileptic drug sodium valproate (300 mg/kg, p.o.). Valproic acid and its salts, sodium or magnesium valproate, are effective anticonvulsants with a broad spectrum of activity [27,28]. Valproic acid increased PTZ thresholds in different seizure types [29,30]. The protective effect of valproic acid on PTZ-induced kindling is believed to be achieved through different neural mechanisms including inhibition of the voltage-dependent sodium channels, augmentation of the concentration of the natural inhibitor GABA in CNS synapses, facilitation of GABAergic neurotransmission, reduction of N-methyl-D-aspartate receptor-mediated glutamate excitation, augmentation of serotonergic inhibition, and attenuation of neurogenic inflammation [31–36]. The effect of F. apodanthera could be mediated by at least one of valproic acid’s mechanisms of action.

Epilepsy has been described as a condition of excessive neuronal discharge associated with or resulting from oxidative stress [37,38]. In addition, high oxidative stress observed during epilepsy yields a consequent limitation on the learning and memory capabilities of patients suffering from seizures [39]. Thus, chemical kindling reflects the convulsive component of this disease as well as secondary alterations in the field of cognition [40]. The results showed that PTZ caused a significant increase in the retention transfer latency in the elevated plus-maze test which

### Table 1

Effects of the lyophilized aqueous extract of Feretia apodanthera on open arm entries, closed arm entries, total arm entries, rearing, head dipping, and ratio of open entries/total entries (OE/TE) versus closed entries/total entries (CE/TE) of mice in the elevated plus-maze test.

<table>
<thead>
<tr>
<th>Treatments</th>
<th>Open arm entries</th>
<th>Closed arm entries</th>
<th>Total arm entries</th>
<th>Ratio of OE/TE vs. CE/TE</th>
<th>Rearing</th>
<th>Head dipping</th>
</tr>
</thead>
<tbody>
<tr>
<td>DW</td>
<td>0.17 ± 0.28</td>
<td>6.33 ± 1.10</td>
<td>6.50 ± 1.33</td>
<td>2.63 ± 0.01</td>
<td>15.50 ± 0.71</td>
<td>6.17 ± 1.44</td>
</tr>
<tr>
<td>FA50</td>
<td>0.50 ± 0.50</td>
<td>5.50 ± 1.17</td>
<td>6.00 ± 1.33</td>
<td>9.09 ± 5.19</td>
<td>11.67 ± 1.14</td>
<td>2.83 ± 0.47**</td>
</tr>
<tr>
<td>FA100</td>
<td>0.67 ± 0.44</td>
<td>1.67 ± 0.67**</td>
<td>2.33 ± 0.44**</td>
<td>40.00 ± 7.36</td>
<td>9.67 ± 2.33</td>
<td>1.33 ± 1.00***</td>
</tr>
<tr>
<td>FA150</td>
<td>1.17 ± 0.28**</td>
<td>1.0 ± 0.00</td>
<td>2.17 ± 0.28**</td>
<td>116.87 ± 12.87***</td>
<td>2.50 ± 0.83***</td>
<td>1.17 ± 0.28**</td>
</tr>
<tr>
<td>FA200</td>
<td>1.33 ± 0.44**</td>
<td>0.67 ± 0.44**</td>
<td>2.00 ± 0.67**</td>
<td>200.00 ± 10.87***</td>
<td>1.17 ± 0.89***</td>
<td>0.67 ± 0.89***</td>
</tr>
<tr>
<td>DZP3</td>
<td>1.50 ± 0.50**</td>
<td>0.50 ± 0.50***</td>
<td>2.00 ± 0.67**</td>
<td>300.00 ± 40.46</td>
<td>0.50 ± 0.50***</td>
<td>0.17 ± 0.28**</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± S.E.M. for 6 animals. DW = distilled water, DZP3 = diazepam 3 mg/kg, and FA50 = lyophilized aqueous extract of F. apodanthera 50 mg/kg.

*p < 0.05, **p < 0.01, ***p < 0.001, compared to the distilled water-treated mice, (two-way ANOVA, followed by Newman-Keuls post hoc test).
Results are expressed as mean ± S.E.M. for 6 animals. DW = distilled water, DZP0.3 = diazepam 0.3 mg/kg, and FA50 = lyophilized aqueous extract of Feretia apodanthera 50 mg/kg.

*p < 0.05, **p < 0.01, ***p < 0.001, compared to the distilled water-treated mice, (two-way ANOVA, followed by Newman-Keuls post hoc test).

Table 2
Effects of the lyophilized aqueous extract of Feretia apodanthera on rearing, crossing, grooming, center time, and quantity of fecal boli in the OF test.

<table>
<thead>
<tr>
<th>Treatments</th>
<th>Rearing</th>
<th>Crossing</th>
<th>Grooming</th>
<th>Fecal boli (g)</th>
<th>Center time [s]</th>
</tr>
</thead>
<tbody>
<tr>
<td>DW 11.67 ± 1.33</td>
<td>8.83 ± 2.11</td>
<td>0.83 ± 0.28</td>
<td>0.28 ± 0.15</td>
<td>4.33 ± 1.67</td>
<td></td>
</tr>
<tr>
<td>FA50 5.67 ± 1.67**</td>
<td>11.83 ± 2.22</td>
<td>1.67 ± 0.44</td>
<td>0.18 ± 0.14</td>
<td>3.33 ± 1.33</td>
<td></td>
</tr>
<tr>
<td>FA100 2.33 ± 0.78***</td>
<td>21.17 ± 4.55**</td>
<td>1.67 ± 0.44</td>
<td>0.11 ± 0.04</td>
<td>7.33 ± 1.33**</td>
<td></td>
</tr>
<tr>
<td>FA150 2.67 ± 0.67***</td>
<td>30.67 ± 3.11***</td>
<td>2.17 ± 0.83**</td>
<td>0.02 ± 0.03**</td>
<td>18.17 ± 0.83**</td>
<td></td>
</tr>
<tr>
<td>FA200 1.83 ± 0.56***</td>
<td>47.17 ± 3.44***</td>
<td>1.67 ± 0.44</td>
<td>0.02 ± 0.04***</td>
<td>32.83 ± 8.83***</td>
<td></td>
</tr>
<tr>
<td>DZP0.3 1.17 ± 0.56***</td>
<td>48.17 ± 7.83***</td>
<td>1.83 ± 0.28</td>
<td>0.02 ± 0.03**</td>
<td>39.17 ± 8.17***</td>
<td></td>
</tr>
</tbody>
</table>

Table 3
Effects of the lyophilized aqueous extract of Feretia apodanthera on the lipid peroxidation product, reduced brain glutathione, and cholinesterase activity in the whole brain of PTZ-kindled mice.

<table>
<thead>
<tr>
<th>Treatments</th>
<th>Dose (mg/kg)</th>
<th>Brain lipid peroxidation</th>
<th>Reduced brain glutathione</th>
<th>Brain cholinergic status</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MDA (nmol/g wet tissue)</td>
<td>GSH (μmol/g wet tissue)</td>
<td>AChE (units)</td>
</tr>
<tr>
<td>DW + saline</td>
<td>- - -</td>
<td>128.754 ± 16.193</td>
<td>199.342 ± 12.471</td>
<td>0.165 ± 0.029</td>
</tr>
<tr>
<td>DW + PTZ</td>
<td>- - 30</td>
<td>427.493 ± 18.157**</td>
<td>101.163 ± 14.294b</td>
<td>0.072 ± 0.005c</td>
</tr>
<tr>
<td>FA + PTZ</td>
<td>50 + 30</td>
<td>415.628 ± 19.416b</td>
<td>138.385 ± 13.358b</td>
<td>0.091 ± 0.007b</td>
</tr>
<tr>
<td>FA + PTZ</td>
<td>100 + 30</td>
<td>178.374 ± 22.639**</td>
<td>142.528 ± 11.275b</td>
<td>0.113 ± 0.003**</td>
</tr>
<tr>
<td>FA + PTZ</td>
<td>150 + 30</td>
<td>137.518 ± 18.491**</td>
<td>173.147 ± 16.328</td>
<td>0.125 ± 0.018**</td>
</tr>
<tr>
<td>FA + PTZ</td>
<td>200 + 30</td>
<td>127.842 ± 21.352**</td>
<td>191.532 ± 12.492</td>
<td>0.139 ± 0.023**</td>
</tr>
<tr>
<td>SVA + PTZ</td>
<td>300 + 30</td>
<td>131.575 ± 10.217***</td>
<td>196.145 ± 12.356</td>
<td>0.145 ± 0.014**</td>
</tr>
<tr>
<td>SVA + saline</td>
<td>300 + 30</td>
<td>110.529 ± 17.145***</td>
<td>198.713 ± 13.715</td>
<td>0.151 ± 0.026**</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± S.E.M. for 6 animals. DW = distilled water, SVA = sodium valproate, and FA = lyophilized aqueous extract of Feretia apodanthera. Cholinesterase activity in the whole mice brain was expressed as μmol of acetylcholine iodide hydrolyzed/mg protein/min and μmol of butyrylcholine iodide hydrolyzed/mg protein/min for AChE and BChE, respectively.

*p < 0.05, **p < 0.01, ***p < 0.001, compared to the distilled water-treated PTZ mice, (two-way ANOVA, followed by Newman-Keuls post hoc test).

*p < 0.05, **p < 0.01, ***p < 0.001, compared to the distilled water + saline-treated mice (two-way ANOVA, followed by Newman-Keuls post hoc test).

indicates impairment of memory in mice. However, F. apodanthera shortened retention transfer latencies, suggesting that F. apodanthera improved the cognition in kindled mice since the mice appeared to remember that there is a closed arm where they could stay safely [41, 42]. Because the reduction of the retention transfer latencies can also be caused by hyperlocomotion, behavioral tests with naive mice were done in the EPM and OF. Feretia apodanthera reduced closed and total arm entries in the EPM. It also reduced rearing and head dipping in the OF. These results suggested that locomotion is not involved in the reduction of transfer latencies by the plant. In the EPM, the aqueous extract of F. apodanthera showed anxiolytic activities by increasing the number of entries in the open arms, the % of entries and time spent into the open arms, and the ratio of open entries/total entries vs. closed entries/total entries and by reducing the number of closed arm entries and the % of closed arm time. These anxiolytic activities of F. apodanthera were confirmed in the OF by the increase of crossing, grooming, and center time. The presence of the anxiolytic properties in F. apodanthera did not affect the retention transfer latencies. The results in the T-maze test with PTZ-kindled mice showed that F. apodanthera reduced the retention transfer latencies but not the initial transfer latencies. If the reduction of the retention transfer latencies was caused by the presence of anxiolytic properties, even the initial transfer latencies could have been reduced. That was not the case. It could then be suggested that F. apodanthera certainly improved memory, for the animals appeared to remember that there was a safe area somewhere (closed arms). The memory improvement induced by F. apodanthera was dose-dependent, with the maximum benefit at the dose of 200 mg/kg. Feretia apodanthera showed antiseizure activity which may be at least partially responsible for the improvement in cognitive function.

To confirm the effect of the aqueous extract of F. apodanthera on spatial short-term memory impairment in PTZ-treated mice, the T-maze test was used to measure spontaneous alternation in which the mice must remember the arm most recently entered to alternate the arm choice [43,44]. The entries and the amount of time spent into the novel arm were lower in the distilled water-treated PTZ mice than in the distilled water + saline-treated mice, and this reduced PTZ-induced spontaneous alternation was reversed by F. apodanthera and sodium valproate. It has been proposed that the time animals spend in the novel arm reflects exploratory behavior while the number of entries into the novel arm reflects inquisitive behavior [45,46]. Since the elevated T-maze did not have open arms, the measurement of anxiolytic effects could not be very appropriate in this test; thus, the exploratory activity in the T-maze induced by F. apodanthera is not attributed to the anxiolytic properties of the plant. Moreover, on the retrial, the fact that animals first entered the familiar arm that contained food before starting to explore the novel arm to search for food suggested that F. apodanthera significantly prevented the spatial short-term memory deficits induced by PTZ.

Free radicals are normal by-products of cellular aerobic metabolism involved in the development of seizures [47]. However, when the production of free radicals increases or the defense mechanism of the body decreases, they cause cellular dysfunction by attacking the polyunsaturated sites of the biological membranes causing lipid peroxidation. In the present study, PTZ kindling increased the level of MDA and decreased the level of GSH in the mouse brain. Pentylenetetrazol thus caused an imbalance between antioxidant and oxidant defense systems which may be at least partially responsible for seizures and cognitive impairment [48]. Feretia apodanthera prevented the rise of brain MDA levels in a dose-dependent manner. The decrease in brain MDA levels by F. apodanthera indicated an inhibition of lipid peroxidation since its increase is a marker of lipid peroxidation [49]. Feretia apodanthera alone also decreased the MDA level which supports its antioxidant property.
Glutathione is an endogenous antioxidant which gets converted to its oxidized form. This oxidized form of reduced glutathione reacts with free radicals and prevents the generation of most toxic hydroxyl radicals [50]. The decrease in reduced glutathione in mouse brain tissue induced by PTZ indicated that during kindling, there was excessive oxidative stress and, as a consequence, glutathione levels were depleted while combating oxidative stress [51,52]. However, *F. apodanthera* in all doses antagonized this decrease and restored the reduced glutathione level in the brain tissues of PTZ-kindled mice.

Seizures decrease choline acetyltransferase and acetylcholinesterase activity in the brain, which may result in cognitive deficit in mice with epilepsy [53]. Thus, significant decreases in acetylcholinesterase and butyrylcholinesterase activity were observed in the distilled water-treated PTZ mice, which might be also related to the development of cognitive impairment. *Feretia apodanthera* provided protection against the development of seizures as a result of which acetylcholinesterase and butyrylcholinesterase activity was not decreased but instead increased. This finding is in accordance with a previous study in which AChE activity was reported to decrease PTZ-induced seizures [54,55]. Taken together, we suggest that *F. apodanthera* had ameliorating effects on memory dysfunction and antagonized cognitive impairment. No mortality was observed for 24 h.

To conclude, a hypolipidized aqueous extract of *F. apodanthera* offered protection against PTZ kindling in mice and antagonized oxidative stress and cognitive impairment in mice. This study thus suggests the potential of *F. apodanthera* as an adjuvant to antiepileptic drugs for patients with epilepsy with dual advantages of better seizure control as well as reduced cognitive impairment. In clinical practice, the administration of *F. apodanthera* to a patient with epilepsy could result first in stopping the memory impairment process and second in repairing memory impairment. However, further biochemical, molecular, and clinical studies are required to ascertain its effectiveness and mechanism of action during epilepsy.

**Acknowledgments**

The authors are very thankful to Smartox Biotechnologies, France, the University of Ngaoundéré, Cameroon, and the University of Buea, Cameroon for their support by providing apparatus and drugs. The authors also appreciate Pierre Biyanzi for his assistance.

**Conflict of interest**

The authors declare no conflict of interest.

**References**


